The Rosen Law Firm announces that it is investigating potential
securities claims against Repros Therapeutics Inc. (NASDAQ: RPRX)
resulting from allegations that the Company may have issued materially
misleading business information to the investing public.
Repros Therapeutics is a development stage biopharmaceutical company
with a focus on developing new drugs to treat hormonal and reproductive
system disorders. Its product portfolio includes Androxal, which treats
low testosterone due to secondary hypogonadism. On September 26, 2014,
Repros Therapeutics announced that the FDA granted the Company a Type B
Pre-New Drug Application (Pre-NDA) meeting in the first half of
November. The Company planned on seeking guidance on its planned new
drug application for Androxal at this meeting. On October 17, 2014,
Repros Therapeutics revealed that the clinical information provided was
insufficient for a Type B Pre-NDA meeting. Rather, a Type C Guidance
meeting would be held instead. On this news, shares of Repros
Therapeutics fell sharply during intraday trading on October 17, 2014,
damaging investors.
The Rosen Law Firm is preparing a class action lawsuit to recover losses
suffered by Repros Therapeutics shareholders as a result of this adverse
information. If you purchased Repros Therapeutics stock on or before
October 17, 2014, please visit the website at http://rosenlegal.com/cases-402.html
for more information. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Copyright Business Wire 2014